Growth restriction and congenital heart disease caused by a novel <em>TAB2</em> mutation: A case report

Deng,Qian; Wang,Xin; Gao,Jian; Xia,Xiaowei; Wang,Yungong; Zhang,Yin; Chen,Yuqing

doi:10.3892/etm.2023.11957

Growth restriction and congenital heart disease caused by a novel TAB2 mutation: A case report

Authors:
- Qian Deng
- Xin Wang
- Jian Gao
- Xiaowei Xia
- Yungong Wang
- Yin Zhang
- Yuqing Chen
View Affiliations

Affiliations: Department of Pediatric Endocrinology and Metabolic Disease, Children's Hospital of Fudan University Anhui Hospital, Hefei, Anhui 230022, P.R. China, Department of Pediatric Endocrinology and Metabolic Disease, Children's Hospital of Fudan University Anhui Hospital, Hefei, Anhui 230022, P.R. China, Department of Ultrasound Medicine, Children's Hospital of Fudan University Anhui Hospital, Hefei, Anhui 230022, P.R. China, Department of Pediatric Cardiovascular Diseases, Children's Hospital of Fudan University Anhui Hospital, Hefei, Anhui 230022, P.R. China, Department of Urology, Children's Hospital of Fudan University Anhui Hospital, Hefei, Anhui 230022, P.R. China
Published online on: April 18, 2023 https://doi.org/10.3892/etm.2023.11957
Article Number: 258
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Congenital heart disease (CHD) is a malformation present from birth caused by the abnormal development of the heart and large blood vessels during the prenatal development. The TGF‑β activated kinase 1 (MAP3K7) binding protein 2 (TAB2) gene plays an important role in the embryonic development of heart tissue. When haploid dosage is insufficient, it can lead to CHD or cardiomyopathy. The present study reported a case study of a Chinese child with growth restriction and CHD. The results of whole exome sequencing suggested that a novel frameshift mutation (c.1056delC/p.Ser353fsTer8) occurred in TAB2. The parents of this patient are wild‑type at this locus; therefore, it may be a de novo mutation. The mutant plasmid was constructed in vitro, and the western blotting results showed that the mutation may cease protein expression. This indicated the pathogenic harmfulness of this mutation. In conclusion, the present study emphasizes that TAB2 defects should be investigated in patients with unexplained short stature and CHD, irrespective of family history regarding CHD or cardiomyopathy. The current study provided new data on the mutation spectrum and provided information for second pregnancies and genetic counseling of the parents of patients.

View Figures

View References

1	Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W and Chen ZJ: Direct activation of protein kinases by unanchored polyubiquitin chains. Nature. 461:114–119. 2009.PubMed/NCBI View Article : Google Scholar
2	Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, et al: TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19:2668–2681. 2005.PubMed/NCBI View Article : Google Scholar
3	Thienpont B, Zhang L, Postma AV, Breckpot J, Tranchevent LC, Van Loo P, Møllgård K, Tommerup N, Bache I, Tümer Z, et al: Haploinsufficiency of TAB2 causes congenital heart defects in humans. Am J Hum Genet. 86:839–849. 2010.PubMed/NCBI View Article : Google Scholar
4	Chen J, Yuan H, Xie K, Wang X, Tan L, Zou Y, Yang Y, Pan L, Xiao J, Chen G and Liu Y: A novel TAB2 nonsense mutation (p.S149X) causing autosomal dominant congenital heart defects: A case report of a Chinese family. BMC Cardiovasc Disord. 20(27)2020.PubMed/NCBI View Article : Google Scholar
5	Ackerman JP, Smestad JA, Tester DJ, Qureshi MY, Crabb BA, Mendelsohn NJ and Ackerman MJ: Whole exome sequencing, familial genomic triangulation, and systems biology converge to identify a novel nonsense mutation in TAB2-encoded TGF-beta activated kinase 1 in a child with polyvalvular Syndrome. Congenit Heart Dis. 11:452–461. 2016.PubMed/NCBI View Article : Google Scholar
6	Ritelli M, Morlino S, Giacopuzzi E, Bernardini L, Torres B, Santoro G, Ravasio V, Chiarelli N, D'Angelantonio D, Novelli A, et al: A recognizable systemic connective tissue disorder with polyvalvular heart dystrophy and dysmorphism associated with TAB2 mutations. Clin Genet. 93:126–133. 2018.PubMed/NCBI View Article : Google Scholar
7	Li H and Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 25:1754–1760. 2009.PubMed/NCBI View Article : Google Scholar
8	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA: The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010.PubMed/NCBI View Article : Google Scholar
9	Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17:405–424. 2015.PubMed/NCBI View Article : Google Scholar
10	Westphal DS, Mastantuono E, Seidel H, Riedhammer KM, Hahn A, Vill K and Wagner M: There is more to it than just congenital heart defects-The phenotypic spectrum of TAB2-related syndrome. Gene. 814(146167)2022.PubMed/NCBI View Article : Google Scholar
11	Engwerda A, Leenders EKSM, Frentz B, Terhal PA, Löhner K, de Vries BBA, Dijkhuizen T, Vos YJ, Rinne T, van den Berg MP, et al: TAB2 deletions and variants cause a highly recognisable syndrome with mitral valve disease, cardiomyopathy, short stature and hypermobility. Eur J Hum Genet. 29:1669–1676. 2021.PubMed/NCBI View Article : Google Scholar
12	Permanyer E, Laurie S, Blasco-Lucas A, Maldonado G, Amador-Catalan A, Ferrer-Curriu G, Fuste B, Perez ML, Gonzalez-Alujas T, Beltran S, et al: A single nucleotide deletion resulting in a frameshift in exon 4 of TAB2 is associated with a polyvalular syndrome. Eur J Med Genet. 63(103854)2020.PubMed/NCBI View Article : Google Scholar
13	Vasilescu C, Ojala TH, Brilhante V, Ojanen S, Hinterding HM, Palin E, Alastalo TP, Koskenvuo J, Hiippala A, Jokinen E, et al: Genetic basis of severe childhood-onset cardiomyopathies. J Am Coll Cardiol. 72:2324–2338. 2018.PubMed/NCBI View Article : Google Scholar
14	Caulfield TR, Richter JE Jr, Brown EE, Mohammad AN, Judge DP and Atwal PS: Protein molecular modeling techniques investigating novel TAB2 variant R347X causing cardiomyopathy and congenital heart defects in multigenerational family. Mol Genet Genomic Med. 6:666–672. 2018.PubMed/NCBI View Article : Google Scholar
15	Liu H, Giguet-Valard AG, Simonet T, Szenker-Ravi E, Lambert L, Vincent-Delorme C, Scheidecker S, Fradin M, Morice-Picard F, Naudion S, et al: Next-generation sequencing in a series of 80 fetuses with complex cardiac malformations and/or heterotaxy. Hum Mutat. 41:2167–2178. 2020.PubMed/NCBI View Article : Google Scholar
16	Hanson J, Brezavar D, Hughes S, Amudhavalli S, Fleming E, Zhou D, Alaimo JT and Bonnen PE: TAB2 variants cause cardiovascular heart disease, connective tissue disorder, and developmental delay. Clin Genet. 101:214–220. 2022.PubMed/NCBI View Article : Google Scholar
17	Cheng A, Dinulos MBP, Neufeld-Kaiser W, Rosenfeld J, Kyriss M, Madan-Khetarpal S, Risheg H, Byers PH and Liu YJ: 6q25.1 (TAB2) microdeletion syndrome: Congenital heart defects and cardiomyopathy. Am J Med Genet A. 173:1848–1857. 2017.PubMed/NCBI View Article : Google Scholar
18	Yin H, Guo X, Chen Y, Zeng Y, Mo X, Hong S, He H, Li J, Steinmetz R and Liu Q: TAB2 deficiency induces dilated cardiomyopathy by promoting RIPK1-dependent apoptosis and necroptosis. J Clin Invest. 132(e152297)2022.PubMed/NCBI View Article : Google Scholar
19	Mifflin L, Ofengeim D and Yuan J: Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 19:553–571. 2020.PubMed/NCBI View Article : Google Scholar